Italfarmaco S.p.A.

• A multicentre, prospective, open-label, non-comparative study to evaluate menstrual bleeding typology, tolerability, and compliance during a… Pending
  2024-519403-10-00 Phase IV 1 country ETHINYLESTRADIOL, NORGESTIMATE
• A Phase 2 Open-label (Core Phase Plus Extension Phase) With 2 Cohorts Study to Assess the Pharmacokinetics and Safety of Givinostat in DMD P… Recruiting
  2024-511823-32-00 Phase II 3 countries GIVINOSTAT
• Phase 3 study to assess the efficacy and safety of Givinostat versus hydroxyurea in Polycythemia Vera patients Recruiting
  2022-502276-23-00 Phase III 11 countries GIVINOSTAT
• Randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy, safety and tolerability of givinostat in non-ambul… Recruiting
  2023-503521-19-00 Phase III 9 countries GIVINOSTAT
• Clinical study to test the safety, tolerance and preliminary efficacy of oral ITF3756 administered alone or in combination with an anti-prot… Recruiting
  2022-501089-22-00 Phase I 2 countries
• Study in which all the patients take the same investigational drug with the aim of evaluate the long-term safety, tolerability, and efficacy… Recruiting
  2023-504520-26-00 Phase III 6 countries GIVINOSTAT
• Long-term study evaluating the effect of givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms Ended
  2024-512413-40-00 Phase II 1 country GIVINOSTAT
• A multicentric, open-label, non-randomized study to evaluate the pharmacokinetic, safety and tolerability of ITF2357 given as an oral single… Ended
  2024-513577-43-00 Phase I (Other) 2 countries

Showing 1–8 of 8 trials